Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FGEN vs CRBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FGEN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

FGEN Overall Winner 6-Pillar Tally: FGEN 3 – 2 CRBP (1 Tie) Matrix Metrics: FGEN 7 – 3 CRBP

As of Nov 16, 2026, FibroGen, Inc (FGEN) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). FGEN carries a Unified Composite Score of 61.2/100 (BUY) at $9.71 (61.4x Forward P/E, -499.1% operating margin), whereas CRBP carries 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2); meanwhile CRBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FGEN vs CRBP
FGEN NASDAQ Head-to-Head Winner
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
TTM Revenue $8.3M
Forward P/E 61.4x
Beta / 30D Vol -20.79β · 102% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.2 · SMA20: $8.88 · SMA50: $9.26
CRBP NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap $69.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 121% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -32.8%), weak momentum, RSI 34
RSI-14: 34.3 · SMA20: $3.83 · SMA50: $5.51

6-Pillar Scorecard Institutional Category Breakdown (FGEN 3 – 2 CRBP)

Columns: Metric · FGEN · CRBP
1. Valuation Multiples FGEN
Forward P/E 61.4x N/M
Trailing P/E 61.4x N/M
PEG Ratio N/M N/M
EV / Revenue 4.4x N/M
2. Growth & Scale FGEN
Revenue Growth (YoY) +774.8% -100.0%
Earnings Growth (YoY) +53.6% +0.0%
TTM Revenue (USD) $8.3M N/A
Market Cap $36.5M $69.9M
3. Profitability & Quality CRBP
Gross Margin N/A N/A
Operating Margin -499.1% 0.0%
Net Profit Margin 2598.9% 0.0%
Return on Equity (ROE) -1015.8% -131.5%
4. Balance Sheet & Cash Flow CRBP
Cash Generation (TTM) -$58M EBITDA -$92M
Cash Flow Margin N/A N/A
Net Cash / Leverage -1015.8% ROE $26M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FGEN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 197.6% (66th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FGEN (7) vs CRBP (3)
Institutional Metric FGEN CRBP Criterion Row Edge
Market Capitalization
Scale
$36.5M $69.9M Larger Scale CRBP
Trailing P/E Ratio
Valuation
61.4x N/M Lower Multiple FGEN
Forward P/E Ratio
Valuation
61.4x N/M Lower Multiple FGEN
Revenue Growth (YoY)
Growth
+774.8% -100.0% Higher Growth FGEN
Operating Margin (TTM)
Profitability
-499.1% 0.0% Higher Margin CRBP
Net Profit Margin
Profitability
2598.9% 0.0% Higher Margin FGEN
Return on Equity (ROE)
Capital Efficiency
-1015.8% -131.5% Higher ROE CRBP
52-Week Range Position
Momentum
44% ($0–$22) 6% ($3–$13) Stronger Trend FGEN
Beta / 30D Volatility
Risk Regime
-20.79β · 102% Vol 1.93β · 121% Vol Lower Realized Risk FGEN
Unified Institutional Score
Composite Signal
61.2 / 100 (BUY) 45.0 / 100 (HOLD) Higher Composite FGEN
Trailing 12M Revenue (USD)
Operating Scale
$8.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M EBITDA (-1015.8% ROE) -$92M ($26M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FGEN +36.3 pp
FGEN: +16.57% · CRBP: -19.73%
3M Horizon FGEN +31.0 pp
FGEN: +7.06% · CRBP: -23.94%
6M Horizon FGEN +31.0 pp
FGEN: +7.06% · CRBP: -23.94%
1Y Horizon FGEN +31.0 pp
FGEN: +7.06% · CRBP: -23.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs CRBP. Trailing 12-month operating profitability (FGEN -499.1% vs CRBP 0.0%) and valuation multiples (FGEN 61.4x vs CRBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.3M
Gross MarginN/A
Op. Margin-499.1%
ROE / Fwd P/E-1015.8% · 61.4x
CRBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-131.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRBP BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 197.6%
IV Percentile 66th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $69.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FGEN vs CRBP Key Questions & Quantitative Answers

As of Nov 16, 2026, FibroGen, Inc (FGEN) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). FGEN carries a Unified Composite Score of 61.2/100 (BUY) at $9.71 (61.4x Forward P/E, -499.1% operating margin), whereas CRBP carries 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2); meanwhile CRBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FGEN leads the Growth & Scale pillar: FGEN posts +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin), compared with CRBP at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FGEN generates $8.3M in USD-normalized revenue versus N/A for CRBP. In operating R&D and SG&A reinvestment, FGEN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRBP.

FGEN screens cheaper on headline valuation multiples. FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin), whereas CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FGEN (-1015.8% ROE) versus CRBP (-131.5% ROE) capital efficiency.

In options market volatility and institutional positioning, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk). By comparison, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.